Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides. METHODS: We sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary artery disease and 29,223 controls. We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid levels in mice and monkeys. RESULTS: We identified 1661 heterozygotes and 17 homozygotes for the E40K variant and 75 participants who had 13 other monoallelic inactivating mutations in ANGPTL4. The levels of triglycerides were 13% lower and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E40K variant than among noncarriers. Carriers of the E40K variant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio, 0.81; 95% confidence interval, 0.70 to 0.92; P=0.002). K40 homozygotes had markedly lower levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes. Carriers of other inactivating mutations also had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coronary artery disease than were noncarriers. Monoclonal antibody inhibition of Angptl4 in mice and monkeys reduced triglyceride levels. CONCLUSIONS: Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, inactivating variants in ANGPTL4, a key inhibitor of LPL, have been shown to reduce levels of TGs, LDL-C, and HDL-C. Individuals with these variants exhibit lifelong reductions in circulating TGs and up to a 19% lower risk of CAD [26].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like mice, humans deficient in ANGPTL3, ANGPTL4, or ANGPTL8 have lower plasma triglycerides (56–58, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
GCTA: a tool for genome-wide complex trait analysis
Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.11.011 · Cited by 8,279
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
A solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Li, B., & Leal, S. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.024 · Cited by 1,527
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Research works printed but not linked: 2
- Van der Auwera GA, 2013, Curr Protoc Bioinformatics, 11, 11.10.1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 201–300 of 497
Triglycerides and Open Angle Glaucoma – A Meta-analysis with meta-regression
Pertl, L., Mossböck, G., Wedrich, A., Weger, M., Königsbrügge, O., Silbernagel, G., & Posch, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-08295-1 · Cited by 35
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Yang, J. X., Song, Q., Niu, S., Chen, H., Petersen, R. B., Zhang, Y., & Huang, K. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30534 · Cited by 35
Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease?
Olshan, D. S., & Rader, D. J. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.01.012 · Cited by 30
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 38
Silbernagel, G., Chen, Y., Li, H., Lemen, D., Wen, Y., Zhen, Y., Rief, M., Kleber, M. E., Delgado, G., Sarzynski, M. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069272 · Cited by 35
“6,9,10 In epidemiological studies, there is always the risk of potential confounding.”
Wen, Y., Zhang, X., Liu, H., Ye, H., Wang, R., Ma, C., Duo, T., Wang, J., Yang, X. Z., Yu, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02520-8 · Cited by 33
Can targeting ANGPTL proteins improve glucose tolerance?
Davies, B. S. J. (2018) · Diabetologia · doi:10.1007/s00125-018-4604-4 · Cited by 31
“Glucose tolerance was not examined in studies that blocked ANGPTL4 action using monoclonal antibodies [8, 21].”
Rong, B., Wu, Q., Reiter, R. J., & Sun, C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.06.024 · Cited by 30
“In view of modern medicine, ANGPTL4 plays a major regulator of plasma TG in multiple physiological stresses, indicating that ANGPTL4 is an essential component of a regulatory circuit to link lipid uptake from dietary and delivery into target tissue.(54,61,62) Thus, in this investigation, we detected the expression of…”
BackgroundDron, J. S., Patel, A. P., Zhang, Y., Jurgens, S. J., Maamari, D. J., Wang, M., Boerwinkle, E., Morrison, A. C., de Vries, P. S., Fornage, M., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.5271 · Cited by 28
Deng, M., Kutrolli, E., Sadewasser, A., Michel, S., Joibari, M. M., Jaschinski, F., Olivecrona, G., Nilsson, S. K., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100237 · Cited by 31
“Human genetic studies have shown that loss-of-function variants in ANGPTL3 are associated with reduced plasma TG and LDL-C levels and a reduced risk of ASCVD (11 – 13).”
InfluentialThe Future of Cardiovascular Therapeutics
MacRae, C. A., Roden, D. M., & Loscalzo, J. (2016) · Circulation · doi:10.1161/circulationaha.116.023555 · Cited by 30
Yang, L., Yu, C., Wang, X., Yuan, S., Zhang, L., Lang, J., Zhao, D., & Feng, Y. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005973 · Cited by 24
Yang, F., Xu, F., Zhang, H., Gill, D., Larsson, S. C., Li, X., Cui, H., & Yuan, S. (2023) · BMC Medicine · doi:10.1186/s12916-023-03197-8 · Cited by 35
Muniyappa, R., Abel, B. S., Asthana, A., Walter, M. F., Cochran, E. K., Remaley, A. T., Skarulis, M. C., Görden, P., & Brown, R. J. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.002 · Cited by 28
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Fowler, A., Sampson, M. L., Remaley, A. T., & Chackerian, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.077 · Cited by 29
Leukocyte–endothelial interaction in CKD
Sarakpi, T., Mesic, A., & Speer, T. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad135 · Cited by 30
Regulation of angiopoietin-like 4 and lipoprotein lipase in human adipose tissue
Dijk, W., Schutte, S., Aarts, E. O., Janssen, I. M. C., Afman, L. A., & Kersten, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.006 · Cited by 30
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
ANGPTL4 Regulates Psoriasis via Modulating Hyperproliferation and Inflammation of Keratinocytes
Zuo, Y., Dai, L., Li, L., Huang, Y., Liu, X., Liu, X., Duan, X., Jiang, S., Deng, G., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.850967 · Cited by 31
“Human genetics studies show that inactivating mutations in the ANGPTL4 gene (E40K) improve glucose and lipid homeostasis and reduce the risk of coronary artery disease and diabetes (Dewey et al., 2016; Stitziel et al., 2016; Liu D. J. et al., 2017; Gusarova et al., 2018).”
BackgroundYang, H. J., Xiao, L., & Xu, D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07001-0 · Cited by 26
“[15] also demonstrated that the injection of REGN1001 (ANGPTL4 monoclonal antibody) significantly reduced the inhibition of LPL activity by ANGPTL4 and promoted a rapid and sustained decrease in the TG level in the plasma of mice and monkeys fed a high-fat diet.”
BackgroundResultInfluentialIncreasing Lipolysis and Reducing Atherosclerosis
Tall, A. R. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706907 · Cited by 26
Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization
Levin, M. G., Kember, R. L., Judy, R., Birtwell, D. L., Williams, H., Arany, Z. P., Giri, J. S., Guerraty, M. A., Cappola, T., Chen, J., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002352 · Cited by 26
Angiopoietin-like proteins in atherosclerosis
Liu, Y., Zhang, C., Jiang, J.-F., Cheng, Z.-B., Zhou, Z., Tang, M.-Y., Sun, J.-X., & Huang, L. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.06.024 · Cited by 28
Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
Sun, T., Zhan, W., Wei, L., Xu, Z., Li, F., Yang, Z., Wang, C., & Zhang, J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01580-z · Cited by 25
“However, some studies have revealed a reduction in plasma triglyceride levels in mice with ANGPTL4 deficiency and inactivation [24, 25].”
BackgroundPrimary tumor–derived systemic nANGPTL4 inhibits metastasis
Hübers, C., Pari, A. A. A., Grieshober, D., Petkov, M., Schmidt, A., Messmer, T., Heyer, C. M., Schölch, S., Kapel, S. S., Gengenbacher, N., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20202595 · Cited by 30
Increased Level of Angiopoietin Like Proteins 4 and 8 in People With Sleep Apnea
Alterki, A., Abu‐Farha, M., Al‐Khairi, I., Cherian, P., Devarajan, S., Shyamsundar, A., Ali, S., Al‐Mulla, F., Tuomilehto, J., & Abubaker, J. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00651 · Cited by 26
Genome-wide studies of heart failure and endophenotypes: lessons learned and future directions
van der Ende, M. Y., Said, M. A., van Veldhuisen, D. J., Verweij, N., & van der Harst, P. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy083 · Cited by 27
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Zhang, Y., Wang, Y., & Liu, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.011 · Cited by 33
Landfors, F., Chorell, E., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100313 · Cited by 25
“Consistent with a causal role of TG in ASCVD, E40K carrier status is associated with a marked decrease in the risk of coronary artery disease (25, 27, 29, 30).”
BackgroundDaniali, M., Galer, P. D., Lewis‐Smith, D., Parthasarathy, S., Kim, E., Salvucci, D. D., Miller, J. M., Haag, S., & Helbig, I. (2022) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2023.102523 · Cited by 27
Kumari, A., Grønnemose, A. L., Kristensen, K. K., Winther, A.-M. L., Young, S. G., Jørgensen, T. J. D., & Ploug, M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221888120 · Cited by 24
Angiopoietin-like 4: A molecular link between insulin resistance and rheumatoid arthritis
Masuko, K. (2017) · Journal of Orthopaedic Research® · doi:10.1002/jor.23507 · Cited by 35
“, E40K) of ANGPTL4 had lower TG levels and a lower CAD risk, thereby suggesting that ANGPTL4 inhibition might be a future therapeutic target for combating ischemic heart disease.(27) The expression of ANGPTL4 occurs mainly in adipose tissue, but also in other organs or tissues, such as the liver, kidney, and lung at a…”
BackgroundVariants in ANGPTL4 and the Risk of Coronary Artery Disease.
Dewey, F. E., Gromada, J., & Shuldiner, A. R. (2016) · PubMed · doi:10.1056/nejmc1607380 · Cited by 11
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
Cho, K. I., Sakuma, I., Sohn, I. S., Hayashi, T., Shimada, K., & Koh, K. K. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1445 · Cited by 25
Lynch Syndrome–Associated Variants and Cancer Rates in an Ancestrally Diverse Biobank
Rosenblum, R. E., Ang, C., Suckiel, S. A., Soper, E. R., Sigireddi, M., Cullina, S., Belbin, G. M., Lucas, A. L., Kenny, E. E., & Abul‐Husn, N. S. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00290 · Cited by 27
“(prevalence) African American/African (n = 6,878) 23 (1:299) 4 (1:1,720) 3 (1:2,293) 7 (1:983) 9 (1:764) Hispanic/Latinx (n = 10,460) 16 (1:654) 4 (1:2,615) 4 (1:2,615) 4 (1:2,615) 4 (1:2,615) European (n = 7,772) 15 (1:518) 3 (1:2,591) 2 (1:3,886) 3 (1:2,591) 7 (1:1,110) South Asian (n = 605) 2 (1:303) 1 (1:605) 0 1…”
Chronic high-fat feeding and prolonged fasting in liver-specific ANGPTL4 knockout mice
Spitler, K. M., Shetty, S. K., Cushing, E. M., Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00144.2021 · Cited by 23
Rutledge, S. M., Soper, E. R., Ma, N., Pejaver, V., Friedman, S. L., Branch, A. D., Kenny, E. E., Belbin, G. M., & Abul-Husn, N. S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.12.025 · Cited by 22
Harada, M., Yamakawa, T., Kashiwagi, R., Ohira, A., Sugiyama, M., Sugiura, Y., Kondo, Y., & Terauchi, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255147 · Cited by 24
“However, ANGPTL4 and ANGPTL8 levels were negatively correlated with HDL-C levels, which is consistent with the previous reports that HDL-C levels are increased by ANGPTL4 deficiency [32, 33].”
ResultMetabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 30
“…inhibitors of LPL, and loss-of-function (LOF) mutations in ANGPTL3 and 4 associate with low triglyceride levels (Romeo et al. 2009; Minicocci et al. 2013; Zhang 2012) and reduced CVD risk (Dewey et al. 2017; Myocardial Infarction Genetics Investigators CAEC et al. 2016; Dewey et al. 2016).”
BackgroundXiao, S., Xue, T., Pan, Q., Hu, Y., Wu, Q., Liu, Q., Wang, X., Liu, A., Liu, J., Zhu, H., et al. (2021) · Cardiovascular Therapeutics · doi:10.1155/2021/2923441 · Cited by 22
“S100A12-mediated osteoblastic genes promote remodeling of atherosclerotic plaques and vascular calcification (26), and the expression of S100A12 in the aorta of atherosclerotic rats is higher than in normal tissues (27).”
BackgroundANGPTL4 attenuates palmitic acid-induced endothelial cell injury by increasing autophagy
Zhan, W., Tian, W., Zhang, W., Tian, H., & Sun, T. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110410 · Cited by 22
Cardioinformatics: the nexus of bioinformatics and precision cardiology
Khomtchouk, B. B., Tran, D.-T. T., Vand, K. A., Might, M., Gozani, O., & Assimes, T. L. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz119 · Cited by 24
“Among the most understood are PCSK9 [68], ANGPTL4 [69, 70] and APOC3 [71] on which association tests and sequencing have been combined to ascertain the linkage to CAD risk, translating to potential vascular protective drugs.”
BackgroundWan, X., Perry, J. A., Zhang, H., Feng, J., Ryan, K. A., Hout, C. V. V., Reid, J. G., Overton, J. D., Baras, A., Han, Z., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020071030 · Cited by 23
Self-citationNordestgaard, A. T., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf337 · Cited by 25
Cho, D. I., Ahn, J. H., Kang, B. G., Hwang, I., Cho, H. H., Jun, J. H., Yoo, J. Y., Cho, M., Yoo, S. J., Kim, H.-S., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322700 · Cited by 25
Computational analysis of neurodevelopmental phenotypes: Harmonization empowers clinical discovery
Lewis‐Smith, D., Parthasarathy, S., Xian, J., Kaufman, M. C., Ganesan, S., Galer, P. D., Thomas, R. H., & Helbig, I. (2022) · Human Mutation · doi:10.1002/humu.24389 · Cited by 21
“These combined resources have been used to identify the protective effect of ANGPTL4 for coronary artery disease and type 2 diabetes (Dewey et al., 2016; Gusarova et al., 2018), and a reduced risk of chronic liver disease in patients with variants in HSD17B13 (Abul ‐ Husn et al., 2018).”
MethodTriglycerides and cardiovascular risk: Apolipoprotein B holds the key
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.004 · Cited by 21
Angiopoietin-like protein 4 and cardiovascular function in COPD
Waschki, B., Kirsten, A., Holz, O., Meyer, T. S., Lichtinghagen, R., Rabe, K. F., MAGNUSSEN, H., Welte, T., Watz, H., & Janciauskiene, S. M. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2016-000161 · Cited by 22
Kumari, A., Larsen, S. W. R., Bondesen, S., Qian, Y., Tian, H., Walker, S. G., Davies, B. S. J., Remaley, A. T., Young, S. G., Konrad, R. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2420721122 · Cited by 22
“The LPL inhibition by ANGPTL3 was slightly greater than the level of inhibition by the loss - of - function E40K ANGPTL4 variant ( 14 , 34 ).”
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 26
“Genetic studies have shown an association between reduced ANGPTL4 gene expression and reduced CVD risk [97–99].”
ANGPTL4: A Comprehensive Review of 25 Years of Research
Ramos, P., Shi, Q., Kleberg, J., Maharjan, C. K., Zhang, W., & Kolb, R. H. (2025) · Cancers · doi:10.3390/cancers17142364 · Cited by 23
“However, this is complicated by studies showing that loss of function of ANGPTL4 or treatment with a blocking antibody significantly lowers hypertriglyceridemia, a known risk factor for atherosclerosis [32,33,93,156], and studies have correlated ANGPTL4 levels with the risk of heart failure [108].”
Okamoto, H., Cavino, K., Na, E., Krumm, E. A., Kim, S. B., Stevis, P. E., Harp, J. B., Murphy, A. J., Yancopoulos, G. D., & Gromada, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620989114 · Cited by 21
“Our data confirm that Angptl4 inhibition lowers plasma triglyceride levels, which may represent a therapeutic strategy for hypertriglyceridemia and could reduce the risk for coronary artery disease (40).”
Self-citationGenetic and Metabolic Determinants of Plasma Levels of ANGPTL8
Oldoni, F., Bass, K., Kozlitina, J., Hudson, H., Shihanian, L. M., Gusarova, V., Cohen, J. C., & Hobbs, H. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab120 · Cited by 21
Self-citationAngiopoietin-like proteins and postprandial partitioning of fatty acids
DiDonna, N., Chen, Y. Q., & Konrad, R. J. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000798 · Cited by 20
“In humans, the ANGPTL4(E40K) mutation has decreased LPL-inhibitory activity [43] and results in reduced triglycerides, increased HDL, and decreased cardiovascular risk, making ANGPTL4 an attractive target [44,45].”
BackgroundSocial Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis
Ko, S., Anzai, A., Liu, X., Kinouchi, K., Yamanoi, K., Torimitsu, T., Ichihara, G., Kitakata, H., Shirakawa, K., Katsumata, Y., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.324638 · Cited by 21
“39,40 Hepatocyte-specific suppression of ANG-PTL4 abates triglyceride and triglyceride-rich cholesterol levels and alleviates atherosclerosis.”
Gao, R., Zhou, P., Li, Y., & Li, Q. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00754-x · Cited by 22
Liu, J., Yagi, K., Nohara, A., Chujo, D., Ohbatake, A., Fujimoto, A., Miyamoto, Y., Kobayashi, J., & Yamagishi, M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.011 · Cited by 20
“In humans, it still remains to be demonstrated whether reductions in the risk of cardiovascular disease will be observed for TG-lowering variants such as those of ANGPTL8 and related proteins.(48) Nevertheless, one of the main strengths of our study is that the findings emphasize the significance of additional hypertr…”
BackgroundTajima, T., Morita, H., Ito, K., Yamazaki, T., Kubo, M., Komuro, I., & Momozawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-26453-x · Cited by 21
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 21
The influence of rare variants in circulating metabolic biomarkers
Riveros-Mckay, F., Oliver‐Williams, C., Karthikeyan, S., Walter, K., Kundu, K., Ouwehand, W. H., Roberts, D. J., Angelantonio, E. D., Soranzo, N., Danesh, J. N., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008605 · Cited by 20
“These approaches enabled, for example, the discovery of inactivating variants in key proteins which are models for drug target antagonism [27,28].”
BackgroundSurma, S., Romańczyk, M., & Filipiak, K. J. (2023) · Cardiology Journal · doi:10.5603/cj.a2021.0006 · Cited by 21
“Less interest in ANGPTL4 as a therapeutic target is due to reported adverse effects such as mesenteric adenitis in rodents treated with anti-ANGPTL4 antibody [41].”
BackgroundKatanasaka, Y., Saito, A., Sunagawa, Y., Sari, N., Funamoto, M., Shimizu, S., Shimizu, K., Akimoto, T., Ueki, C., Kitano, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092449 · Cited by 20
“Two large clinical studies indicate that a loss-of-function mutation (E40K) in ANGPTL4 is associated with reduced plasma TG and risk of CAD [10,11].”
BackgroundResultColesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 29
Macromolecular Interactions of Lipoprotein Lipase (LPL)
Wheless, A., Gunn, K. H., & Neher, S. B. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-58843-3_8 · Cited by 20
Girelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 19
“On the other hand, a number of NGS-based studies focusing on the main genes involving in modulation of the LPL pathway (APOA5, APOC3, ANGPTL4, and the LPL gene itself), often using the same strategy as above, i.e. initially focusing on individuals with extremely high or low plasma triglycerides levels, have yielded re…”
BackgroundInfluentialSemenkovich, C. F. (2017) · Diabetes · doi:10.2337/db17-0093 · Cited by 19
“Circulating triglycerides predict macrovascular disease and specific genetic variants responsible for this effect have been identified (9,10), but triglycerides are not major components of vascular lesions.”
BackgroundTriglyceride-Rich Lipoproteins
Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 22
Ruotsalainen, S., Surakka, I. L., Mars, N., Karjalainen, J. M., Kurki, M., Kanai, M., Krebs, K., Graham, S. E., Mishra, P. P., Mishra, B. H., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03552-0 · Cited by 23
Advances in new therapeutic targets for atherosclerosis
Tang, W. H. W., & Hazen, S. L. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.216 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
“pared with noncarriers and carriers of ANGPTL4-reducing mutations had a 19% lower CAD risk compared with noncarriers.(81) An analysis of 72,868 patients with CAD and 120,770”
ResultImpact of loss-of-function in angiopoietin-like 4 on the human phenome
Gagnon, E., Bourgault, J., Gobeil, É., Thériault, S., & Arsenault, B. J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117558 · Cited by 17
Modder, M., Panhuis, W. I. H., Li, M., Afkir, S., Dorn, A. L., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., Pierrou, S. E., Nilsson, S. K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae195 · Cited by 20
Shen, X., Weng, C., Wang, Y., Wang, C., Feng, S., Li, X., Li, H., Jiang, H., Wang, H., & Chen, J. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.07.005 · Cited by 17
RetractedShivakumar, M., Miller, J. E., Dasari, V. R., Gogoi, R. P., & Kim, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00574 · Cited by 21
Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients
Wang, T., Xu, J., Fu, L., & Li, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13508 · Cited by 18
“Age (y), median (range) 50 (27-70) 49 (23-69) 48 (26-70)”
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 22
The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.046 · Cited by 21
“Several studies have evaluated the added value of including genetic information in classic risk scales.77–103 Almost all of these studies report an association between genetic variants and IHD risk that is independent of established cardiovascular risk factors and a family history of IHD.”
BackgroundInfluentialPost-Selection Estimation and Testing Following Aggregate Association Tests
Heller, R., Meir, A., & Chatterjee, N. (2019) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/rssb.12318 · Cited by 19
“The variant E40K is indeed associated with TG, as validated by external studies (Dewey et al., 2016).”
BackgroundYang, Q., Yin, R., Cao, X., Huang, F., Zhou, Y., & Chen, W. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0308-5 · Cited by 17
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 21
Huang, Y.-T., Ma, R., Xu, Y., Zhong, K., Bu, Q., & Gao, H. X. (2021) · Foods · doi:10.3390/foods11010004 · Cited by 16
“TG is a major health risk factor, and consuming higher than normal levels could induce cardiovascular diseases like atherosclerosis [28].”
BackgroundAarsetoey, R., Ueland, T., Aukrust, P., Michelsen, A. E., de la Fuente, R. L., Pönitz, V., Brügger‐Andersen, T., Grundt, H., Staines, H., & Nilsen, D. W. T. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13339 · Cited by 16
Zhu, X., Zhang, X., Gu, W., Zhao, H., Hao, S., & Ning, Z. (2023) · PubMed Central · doi:10.22038/ijbms.2023.69196.15077 · Cited by 26
“Several studies showed that the down-regulation of ANGPTL4 is substantially correlated with lower levels of TG and a lower risk of cardiovascular events (19-21).”
BackgroundEvaluation of Plasma Biomarkers for Causal Association With Peripheral Artery Disease
Sharma, P., Levin, M. G., Klarin, D. M., Voight, B. F., Tsao, P. S., & Damrauer, S. M. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320674 · Cited by 15
“45 Clinical trials have primarily focused on a similar target, ANGPTL3, with evinacumab (Food and Drug Administration approved as Evkeeza), a monoclonal antibody against ANGPTL3, being shown to effectively lower LDL in patients with homozygous familial hypercholesterolemia receiving the maximum…”
BackgroundVahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates
Cummings, B. B., Bouchard, P. R., Milton, M., Moesta, P. F., Ramanan, V., Trauger, J. W., Maratos–Flier, E., Voznesensky, A., Splawski, I., Nimonkar, A. V., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105748 · Cited by 17
“…to date, pharmacological ANGPTL4 inhibition has not resulted in any fi ndings beyond subclinical histopathological fi ndings localised to the MLNs. 16,17 It has been reported that Angptl4 -knockout mice on an HSFD exhibit developmental defects, including thickening of the small intestine and…”
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 15
“Subsequent studies found similar observations which led to the identification of other ANGPTL4 LoF variants [18, 38, 39].”
Musunuru, K., Arora, P. K., Cooke, J. P., Ferguson, J. F., Hershberger, R. E., Hickey, K. T., Lee, J., Lima, J. A. C., Loscalzo, J., Pereira, N. L., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000046 · Cited by 16
LILRB3 genetic variation is associated with kidney transplant failure in African American recipients
Sun, Z., Yi, Z., Wei, C., Wang, W., Ren, T., Cravedi, P., Tedla, F. M., Ward, S. C., Azeloglu, E. U., Schrider, D. R., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03568-z · Cited by 13
“The sample preparation, exome sequencing, quality control and SNP calling were conducted at the Regeneron Genetics Center as described in a previous publication 57 with GATK best practice.”
Kjellqvist, S., Klose, C. D., Surma, M. A., Hindy, G., Mollet, I. G., Johansson, A., Chavaux, P., Gottfries, J., Simons, K., Melander, O., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004503 · Cited by 13
Angiopoietin-like 4 governs diurnal lipoprotein lipase activity in brown adipose tissue
van Eenige, R., Panhuis, W. I. H., Schönke, M., Jouffe, C., Devilee, T. H., Siebeler, R., Streefland, T. C. M., Sips, H. C. M., Pronk, A. C. M., Vorderman, R. H. P., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101497 · Cited by 16
de Armas‐Rillo, L., Quevedo-Abeledo, J. C., Hernández-Hernández, V., de Vera-González, A., Delgado, A. G., García-Dopico, J. A., González-Gay, M. Á., & Ferraz‐Amaro, I. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02784-z · Cited by 14
“Similarly, carriers of inactivating mutations in ANGPTL4 exhibit lower triglyceride levels and a lower risk of coronary artery disease than non-carriers [6].”
BackgroundZarkasi, K. A., Abdullah, N., Murad, N. A. A., Ahmad, N., & Jamal, R. (2022) · Diagnostics · doi:10.3390/diagnostics12102561 · Cited by 16
Zhang, Y., Zhang, Z.-T., Wan, S.-Y., Yang, J. X., Wei, Y., Chen, H., Zhou, W.-Z., Song, Q., Niu, S., Zheng, L., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad053 · Cited by 14
“Moreover, genetic evidence suggests that protein mutants/variants of ANGPTL4 or ANGPTL8 are related to the risk of hypolipidemia ( Dewey et al., 2016 ; Helkkula et al., 2021 ) .”
Replication and fine-mapping of genetic predictors of lipid traits in African–Americans
Feng, Q., Wei, W., Levinson, R. T., Mosley, J. D., & Stein, C. M. (2017) · Journal of Human Genetics · doi:10.1038/jhg.2017.55 · Cited by 13
“In Caucasians, efforts have been made to identify and understand low-frequency variants for LDL-C (12); however, less is known in AAs particularly for other lipid traits, such as HDL-C,TC, and TG although they are associated with CAD risk (13).”
BackgroundExome-based investigation of the genetic basis of human pigmentary glaucoma
van der Heide, C. J., Goar, W., Meyer, K. J., Alward, W. L. M., Boese, E. A., Sears, N. C., Roos, B. R., Kwon, Y. H., DeLuca, A. P., Siggs, O. M., et al. (2021) · BMC Genomics · doi:10.1186/s12864-021-07782-0 · Cited by 13
“Whole exome sequencing of the Iowa cohort was performed on PDS patient and control subject DNA at the same time using the same capture system as previously described [28] in collaboration with Regeneron, Inc.”
MethodSchinzari, F., Vizioli, G., Campia, U., Tesauro, M., & Cardillo, C. (2021) · Biomedicines · doi:10.3390/biomedicines9081037 · Cited by 13
“experimental observations, population-based studies have shown that loss-of-function variants of either Angptl3 or Angptl4 are associated with lower plasma triglycerides and a decreased risk of cardiovascular disease [9,10].”
BackgroundShen, X., Wang, H., Weng, C., He, Y., Shao, X., Le, J., Chen, H., Shen, Q., Chen, J., & Jiang, H. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.025 · Cited by 13
Jiang, S., Ren, Z., Yang, Y., Liu, Q., Zhou, S., & Xiao, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115874 · Cited by 15
Metadata
- Authors
- Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., Leader, J. B., Murray, M. F., Ritchie, M. D., Kirchner, H. L., Ledbetter, D. H., Penn, J., Lopez, A., Borecki, I. B., Overton, J. D., Reid, J. G., Carey, D. J., Murphy, A. J., Yancopoulos, G. D., Baras, A., Gromada, J., & Shuldiner, A. R.
- Affiliations
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-24
- Volume
- 374
- Issue
- 12
- Pages
- 1123-1133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4900689
- OpenAlex
- W2323589075
- Cited by
- 497
- References
- 40
- Citations by year
- 2026: 33 · 2025: 40 · 2024: 38 · 2023: 36 · 2022: 41 · 2021: 63 · 2020: 52 · 2019: 51 · 2018: 53 · 2017: 57 · 2016: 33
- FWCI
- 53.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- ANGPTL4, loss-of-function mutations, coronary artery disease, triglycerides, HDL cholesterol, lipoprotein lipase, genetic variants, monoclonal antibody inhibition, serum lipids, genetic association studies
- MeSH terms
- Angiopoietin-Like Protein 4, Aged, Animals, Cholesterol, Coronary Artery Disease, Disease Models, Animal, Female, Heterozygote, Humans, Macaca mulatta, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Gene Silencing, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.